association

Full identifier: http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#association

Assigned to 1 class:

Minted in Nanopublication

 RAZFqdakeG comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAZFqdakeG...#association association https://w3id.org/biolink/vocab/has_population_context has_population_context This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAZFqdakeG...#context context .
This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAZFqdakeG...#context context http://www.w3.org/2000/01/rdf-schema#label label "adults" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAZFqdakeG... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78].
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:49.145Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)